James R. Anderson

23.0k total citations · 3 hit papers
232 papers, 14.4k citations indexed

About

James R. Anderson is a scholar working on Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, James R. Anderson has authored 232 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Pulmonary and Respiratory Medicine, 68 papers in Pathology and Forensic Medicine and 68 papers in Oncology. Recurrent topics in James R. Anderson's work include Sarcoma Diagnosis and Treatment (91 papers), Lymphoma Diagnosis and Treatment (40 papers) and Renal and related cancers (40 papers). James R. Anderson is often cited by papers focused on Sarcoma Diagnosis and Treatment (91 papers), Lymphoma Diagnosis and Treatment (40 papers) and Renal and related cancers (40 papers). James R. Anderson collaborates with scholars based in United States, Canada and United Kingdom. James R. Anderson's co-authors include William H. Meyer, Sarah S. Donaldson, David M. Parham, Harold M. Maurer, Douglas S. Hawkins, William M. Crist, John C. Breneman, R. Beverly Raney, Moody D. Wharam and Stephen J. Qualman and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

James R. Anderson

227 papers receiving 14.1k citations

Hit Papers

3 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD

1992 813 citations James R. Anderson, Nis I. Nissen et al. profile →
Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease

2001 737 citations William M. Crist, James R. Anderson et al. Journal of Clinical Oncology profile →
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

2019 703 citations Georgina V. Long, Omid Hamid et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James R. Anderson United States	66	7.3k	4.5k	4.3k	2.9k	2.7k	232	14.4k
Andrea Ferrari Italy	61	7.2k 1.0×	3.2k 0.7×	4.7k 1.1×	1.7k 0.6×	3.6k 1.3×	486	14.3k
Paul A. Meyers United States	66	9.0k 1.2×	2.1k 0.5×	4.2k 1.0×	4.2k 1.4×	2.3k 0.9×	262	15.7k
Mark Krailo United States	76	6.8k 0.9×	2.7k 0.6×	5.7k 1.3×	4.5k 1.5×	4.1k 1.5×	392	18.7k
Winette T.A. van der Graaf Netherlands	69	6.4k 0.9×	1.9k 0.4×	7.2k 1.7×	2.4k 0.8×	2.6k 0.9×	574	17.7k
Michael P. Link United States	55	4.5k 0.6×	2.5k 0.6×	2.5k 0.6×	1.5k 0.5×	1.6k 0.6×	145	9.9k
Lois B. Travis United States	62	3.4k 0.5×	3.4k 0.8×	4.8k 1.1×	1.7k 0.6×	2.5k 0.9×	183	14.0k
Carlos Rodríguez‐Galindo United States	63	3.7k 0.5×	1.6k 0.4×	4.1k 0.9×	2.6k 0.9×	3.5k 1.3×	356	13.7k
Helmut Gadner Austria	73	4.8k 0.7×	3.3k 0.7×	3.9k 0.9×	2.9k 1.0×	3.2k 1.2×	408	20.4k
Holcombe E. Grier United States	57	5.7k 0.8×	1.8k 0.4×	2.4k 0.5×	2.0k 0.7×	2.0k 0.7×	145	11.7k
Jeremy Whelan United Kingdom	48	5.2k 0.7×	1.8k 0.4×	3.4k 0.8×	1.3k 0.5×	1.4k 0.5×	194	9.6k

Countries citing papers authored by James R. Anderson

Since Specialization

Citations

This map shows the geographic impact of James R. Anderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Anderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Anderson more than expected).

Fields of papers citing papers by James R. Anderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Anderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Anderson. The network helps show where James R. Anderson may publish in the future.

Co-authorship network of co-authors of James R. Anderson

This figure shows the co-authorship network connecting the top 25 collaborators of James R. Anderson. A scholar is included among the top collaborators of James R. Anderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James R. Anderson. James R. Anderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robert, Caroline, Matteo S. Carlino, Catriona M. McNeil, et al.. (2023). Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. Journal of Clinical Oncology. 41(24). 3998–4003. 63 indexed citations

Mascarenhas, Leo, Yueh-Yun Chi, Pooja Hingorani, et al.. (2019). Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group. Journal of Clinical Oncology. 37(31). 2866–2874. 75 indexed citations

Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674. 336 indexed citations

Fernandez, Conrad V., Elizabeth A. Mullen, Yueh‐Yun Chi, et al.. (2017). Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children’s Oncology Group Study AREN0532. Journal of Clinical Oncology. 36(3). 254–261. 59 indexed citations

Hingorani, Pooja, Edoardo Missiaglia, Janet Shipley, et al.. (2015). Clinical Application of Prognostic Gene Expression Signature in Fusion Gene–Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research. 21(20). 4733–4739. 17 indexed citations

Walterhouse, David, Alberto S. Pappo, Jane L. Meza, et al.. (2014). Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Journal of Clinical Oncology. 32(31). 3547–3552. 100 indexed citations

Rudzinski, Erin R., Lisa A. Teot, James R. Anderson, et al.. (2013). Dense Pattern of Embryonal Rhabdomyosarcoma, a Lesion Easily Confused With Alveolar Rhabdomyosarcoma. American Journal of Clinical Pathology. 140(1). 82–90. 66 indexed citations

Weiss, Aaron R., Elizabeth Lyden, James R. Anderson, et al.. (2013). Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee. Journal of Clinical Oncology. 31(26). 3226–3232. 75 indexed citations

Smith, Lynette M., James R. Anderson, Minnie Abromowitch, et al.. (2012). The immunophenotype of T ‐lymphoblastic lymphoma in children and adolescents: a C hildren's O ncology G roup report. British Journal of Haematology. 159(4). 454–461. 69 indexed citations

10.

Grundy, Paul E., et al.. (2012). Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies‐4 and ‐5: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 59(4). 631–635. 38 indexed citations

11.

Giles, Natalie, James R. Anderson, Jacqueline K. Phillips, et al.. (2011). Changes in cutaneous innervation in patients with chronic pain after burns. Burns. 37(4). 631–637. 42 indexed citations

12.

Mascarenhas, Leo, Elizabeth Lyden, Philip P. Breitfeld, et al.. (2010). Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 28(30). 4658–4663. 80 indexed citations

13.

Perlman, Elizabeth J., Paul E. Grundy, James R. Anderson, et al.. (2010). WT1 Mutation and 11P15 Loss of Heterozygosity Predict Relapse in Very Low-Risk Wilms Tumors Treated With Surgery Alone: A Children's Oncology Group Study. Journal of Clinical Oncology. 29(6). 698–703. 54 indexed citations

14.

Cairo, Mitchell S., Richard Sposto, Anna T. Meadows, et al.. (2002). Childhood and adolescent large‐cell lymphoma (LCL): A review of the children's cancer group experience. American Journal of Hematology. 72(1). 53–63. 30 indexed citations

15.

Lin, Ming‐Fong, Ming‐Shyue Lee, Tzu‐Ching Meng, et al.. (2001). DECREASED EXPRESSION OF CELLULAR PROSTATIC ACID PHOSPHATASE INCREASES TUMORIGENICITY OF HUMAN PROSTATE CANCER CELLS. The Journal of Urology. 166(5). 1943–1950. 64 indexed citations

16.

Raney, R. Beverly, James R. Anderson, Frederic G. Barr, et al.. (2001). Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V. The American journal of pediatric hematology/oncology. 23(4). 215–220. 273 indexed citations

17.

Raney, R. Beverly, James R. Anderson, Richard J. Andrassy, et al.. (2000). Soft-Tissue Sarcomas of the Diaphragm: A Report From the Intergroup Rhabdomyosarcoma Study Group From 1972 to 1997. The American journal of pediatric hematology/oncology. 22(6). 510–514. 14 indexed citations

18.

Lawrence, Walter, James R. Anderson, Edmund A. Gehan, & Harold M. Maurer. (1997). Pretreatment TNM staging of childhood rhabdomyosarcoma. Cancer. 80(6). 1165–1170. 176 indexed citations

19.

Case, Delvyn C., James R. Anderson, Thomas J. Ervin, & Arlan J. Gottlieb. (1991). Phase II trial of ifosfamide and mesna in previously treated patients with non‐hodgkin's lymphoma: Cancer and leukemia group b study 8552. Hematological Oncology. 9(4-5). 189–196. 6 indexed citations

20.

Gottlieb, Arlan J., James R. Anderson, Sandra J. Ginsberg, et al.. (1990). A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas cancer and leukemia group B study 7851. Cancer. 66(9). 1888–1896. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact